Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-Term Outcome of Proton Therapy and Carbon-Ion Therapy for Large (T2a– T2bN0M0) Non–Small-Cell Lung Cancer  Hiromitsu Iwata, MD, PhD, Yusuke Demizu,

Published byAleksi Kouki Modified over 5 years ago

Similar presentations

Presentation on theme: "Long-Term Outcome of Proton Therapy and Carbon-Ion Therapy for Large (T2a– T2bN0M0) Non–Small-Cell Lung Cancer  Hiromitsu Iwata, MD, PhD, Yusuke Demizu,"— Presentation transcript:

1 Long-Term Outcome of Proton Therapy and Carbon-Ion Therapy for Large (T2a– T2bN0M0) Non–Small-Cell Lung Cancer  Hiromitsu Iwata, MD, PhD, Yusuke Demizu, MD, PhD, Osamu Fujii, MD, PhD, Kazuki Terashima, MD, PhD, Masayuki Mima, MD, Yasue Niwa, MD, Naoki Hashimoto, MD, PhD, Takashi Akagi, PhD, Ryohei Sasaki, MD, PhD, Yoshio Hishikawa, MD, PhD, Mitsuyuki Abe, MD, PhD, Yuta Shibamoto, MD, PhD, Masao Murakami, MD, PhD, Nobukazu Fuwa, MD, PhD  Journal of Thoracic Oncology  Volume 8, Issue 6, Pages (June 2013) DOI: /JTO.0b013e318288ab02 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Example of particle therapy planning for T2a non–small-cell carcinoma. A, Proton therapy with one portal; (B), carbon-ion therapy with one portal; (C), proton therapy with coplanar two portals; and (D), carbon-ion therapy with coplanar two portals. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318288ab02) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A, Overall survival; (B), local control; and (C), progression-free survival curves after particle therapy for all (•), T2a (○), and T2b (Δ) patients. A, p = 0.65; (B), p = 0.75; and (C), p = 0.82. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318288ab02) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 A, Overall survival; (B), local control; (C), and progression-free survival curves after particle therapy for operable (○) and inoperable (• ) patients. A, p = 0.018; (B), p = 0.54; (C), p = 0.82. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318288ab02) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 A, Overall survival; (B), local control, and (C), progression-free survival curves for patients receiving (• ) or (○). A, p = 0.80; (B), p = 0.85; and (C), p = PT, proton therapy; CIT, carbon-ion therapy. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318288ab02) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 A, Overall survival; (B), local control; (C), and progression-free survival curves for patients withadenocarcinoma (• ) and with squamous cell carcinoma SCC (○). A, p = 0.045; (B), p = 0.24; (C), p = 0.54. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318288ab02) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Long-Term Outcome of Proton Therapy and Carbon-Ion Therapy for Large (T2a– T2bN0M0) Non–Small-Cell Lung Cancer  Hiromitsu Iwata, MD, PhD, Yusuke Demizu,"

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.
Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.
Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Results of Surgical Treatment for Patients with Small Cell Lung Cancer
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Similar presentations

Ads by Google